



Oral Pharmacologic Treatment of Type 2 Diabetes

Guest Editor:

Dr. Juan José Gorgojo-Martínez

Unidad de Endocrinología y
Nutrición, Fundación Hospital
Alcorcón, 28922 Madrid, Spain

Deadline for manuscript
submissions:

15 June 2024

Message from the Guest Editor

Currently, there are 12 classes of glucose-lowering drugs (GLD) marketed in the world, and this number is expected to keep growing in the coming years. Therefore, T2DM therapy in the XXI century will require expert knowledge of the advantages and disadvantages of each available drug and the possibility of a rational combination based on phenotype, pathophysiology, and pharmacogenomics—in other words, precision diabetology.

In recent years, several GLDs with weight-loss properties from two therapeutic families, GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter type 2 inhibitors (SGLT-2i), have shown a reduction in CV and renal morbidity and mortality in patients with T2DM. All types of SGLT-2i and one GLP-1RA (semaglutide) are available as oral drugs.

We are living in an exciting era in the pharmacological treatment of T2DM. We look forward to receiving your submissions to this Special Issue.

Dr. Juan José Gorgojo-Martínez
Collection Editor





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care
Medicine, University of Tokyo,
Tokyo, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) / CiteScore - Q1 (*General Medicine*)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)